Security key
034569103
Anebulo Pharmaceuticals, Inc. - Common Stock (ANEB)
CUSIP: 034569103
Q4 2025 13F Holders as of 31 Dec 2025
- Type / Class
- Equity / Common Stock
- Shares outstanding
- 41,587,315
- Total 13F shares
- 6,741,386
- Share change
- -11,077
- Total reported value
- $6,808,914
- Price per share
- $1.01
- Number of holders
- 16
- Value change
- -$68,403
- Number of buys
- 6
- Number of sells
- 10
Report period
Q4 2025
Institutions
16
Top holders
10
ANEB full security history
Newer quarter: Q1 2026
Previous quarter: Q3 2025
Anebulo Pharmaceuticals, Inc. SEC filings
Anebulo Pharmaceuticals, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 034569103
Recent filing periods:
Top shareholders of ANEB - Anebulo Pharmaceuticals, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Aron R. English |
13D/G
3/4/5
|
Director, 10%+ Owner |
51%
|
21,929,880
|
$25,877,258 | $0 | 24 Feb 2025 | |
| Nantahala Capital Management, LLC |
13F
13D/G
|
Company |
8.5%
from 13D/G
|
3,036,325
|
$7,590,812 | — | 30 Sep 2025 | |
| MANGROVE PARTNERS IM, LLC |
13F
13D/G
|
Company |
6.2%
from 13D/G
|
2,525,252
|
$6,313,130 | — | 30 Sep 2025 | |
| 22NW, LP |
13F
|
Company |
37%
|
15,467,300
|
$38,668,250 | — | 30 Sep 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.96%
|
399,404
|
$998,511 | — | 30 Sep 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
0.74%
|
306,540
|
$766,351 | — | 30 Sep 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.42%
|
174,108
|
$435,570 | — | 30 Sep 2025 | |
| Ikarian Capital, LLC |
13F
|
Company |
0.38%
|
157,720
|
$394,300 | — | 30 Sep 2025 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.07%
|
28,500
|
$71,250 | — | 30 Sep 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.06%
|
24,393
|
$60,983 | — | 30 Sep 2025 | |
| BlackRock, Inc. |
13F
|
Company |
0.06%
|
24,060
|
$60,150 | — | 30 Sep 2025 | |
| Rangeley Capital, LLC |
13F
|
Company |
0.05%
|
20,000
|
$50,000 | — | 30 Sep 2025 | |
| XTX Topco Ltd |
13F
|
Company |
0.05%
|
19,153
|
$47,883 | — | 30 Sep 2025 | |
| BOOTHBAY FUND MANAGEMENT, LLC |
13F
|
Company |
0.05%
|
18,836
|
$47,090 | — | 30 Sep 2025 | |
| STATE STREET CORP |
13F
|
Company |
0.03%
|
12,768
|
$31,920 | — | 30 Sep 2025 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0.01%
|
2,138
|
$5,345 | — | 30 Sep 2025 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0%
|
1,750
|
$4,375 | — | 30 Sep 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0%
|
891
|
$2,228 | — | 30 Sep 2025 | |
| BARCLAYS PLC |
13F
|
Company |
0%
|
399
|
$998 | — | 30 Sep 2025 | |
| UBS Group AG |
13F
|
Company |
0%
|
220
|
$550 | — | 30 Sep 2025 | |
| CITIGROUP INC |
13F
|
Company |
0%
|
6
|
$15 | — | 30 Sep 2025 | |
| Joseph F. Lawler |
3/4/5
|
Director, 10%+ Owner |
—
class O/S missing
|
13,236
|
— | — | 04 Apr 2025 | |
| Richard Anthony Cunningham |
3/4/5
|
Chief Executive Officer, Director |
—
class O/S missing
|
316,352
|
— | — | 04 Apr 2025 | |
| Kenneth C. Cundy |
3/4/5
|
Chief Scientific Officer |
—
class O/S missing
|
115,037
|
— | — | 04 Apr 2025 | |
| Simon Allen |
3/4/5
|
Chief Executive Officer, Director |
—
class O/S missing
|
70,246
|
— | — | 09 Dec 2022 | |
| Karah Herdman Parschauer |
3/4/5
|
Director |
—
class O/S missing
|
30,425
|
— | — | 21 Apr 2022 | |
| Bimal R. Shah |
3/4/5
|
Director |
—
class O/S missing
|
6,618
|
— | — | 04 Apr 2025 | |
| Jason Aryeh |
3/4/5
|
Director |
—
class O/S missing
|
4,964
|
— | — | 04 Apr 2025 | |
| Kenneth Lin |
3/4/5
|
Director |
—
class O/S missing
|
4,964
|
— | — | 04 Apr 2025 | |
| Nathaniel Calloway |
3/4/5
|
Director |
—
class O/S missing
|
3,309
|
— | — | 04 Apr 2025 | |
| Areta Kupchyk |
3/4/5
|
Director |
—
class O/S missing
|
2,647
|
— | — | 04 Apr 2025 |
Institutional Holders of Anebulo Pharmaceuticals, Inc. - Common Stock (ANEB) as of Q4 2025
As of 31 Dec 2025,
Anebulo Pharmaceuticals, Inc. - Common Stock (ANEB) was held by
16 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
6,741,386 shares.
The largest 10 holders included
Nantahala Capital Management, LLC, MANGROVE PARTNERS IM, LLC, VANGUARD GROUP INC, MORGAN STANLEY, GEODE CAPITAL MANAGEMENT, LLC, Rangeley Capital, LLC, RENAISSANCE TECHNOLOGIES LLC, CITADEL ADVISORS LLC, BlackRock, Inc., and NORTHERN TRUST CORP.
This page lists
16
institutional shareholders reporting positions in this security
for the Q4 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q4 2025 vs Q3 2025 Across Filers
Q3 2025 holders
20
Q4 2025 holders
16
Holder diff
-4
| Investor | Q3 2025 Shares | Q4 2025 Shares | Share Diff | Share Chg % | Q3 2025 Value $ | Q4 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.